Literature DB >> 33682714

Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment.

Alexandra L Clark1,2,3, Alexandra J Weigand1,4, Kelsey R Thomas1,3, Seraphina K Solders5, Lisa Delano-Wood1,2,3, Mark W Bondi1,2,3, Rachel A Bernier5, Erin E Sundermann3, Sarah J Banks5, Katherine J Bangen1,3.   

Abstract

BACKGROUND: Age-related cerebrovascular and neuroinflammatory processes have been independently identified as key mechanisms of Alzheimer's disease (AD), although their interactive effects have yet to be fully examined.
OBJECTIVE: The current study examined 1) the influence of pulse pressure (PP) and inflammatory markers on AD protein levels and 2) links between protein biomarkers and cognitive function in older adults with and without mild cognitive impairment (MCI).
METHODS: This study included 218 ADNI (81 cognitively normal [CN], 137 MCI) participants who underwent lumbar punctures, apolipoprotein E (APOE) genotyping, and cognitive testing. Cerebrospinal (CSF) levels of eight pro-inflammatory markers were used to create an inflammation composite, and amyloid-beta 1-42 (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau) were quantified.
RESULTS: Multiple regression analyses controlling for age, education, and APOE ɛ4 genotype revealed significant PP x inflammation interactions for t-tau (B = 0.88, p = 0.01) and p-tau (B = 0.84, p = 0.02); higher inflammation was associated with higher levels of tau within the MCI group. However, within the CN group, analyses revealed a significant PP x inflammation interaction for Aβ42 (B = -1.01, p = 0.02); greater inflammation was associated with higher levels of Aβ42 (indicative of lower cerebral amyloid burden) in those with lower PP. Finally, higher levels of tau were associated with poorer memory performance within the MCI group only (p s < 0.05).
CONCLUSION: PP and inflammation exert differential effects on AD CSF proteins and provide evidence that vascular risk is associated with greater AD pathology across our sample of CN and MCI older adults.

Entities:  

Keywords:  Cerebrospinal fluid; inflammation; mild cognitive impairment; tau; vascular dysfunction

Mesh:

Substances:

Year:  2021        PMID: 33682714      PMCID: PMC9052932          DOI: 10.3233/JAD-201382

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.160


  60 in total

Review 1.  Cholinergic control of inflammation.

Authors:  M Rosas-Ballina; K J Tracey
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

2.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

3.  Long-term efficacy and safety of celecoxib in Alzheimer's disease.

Authors:  Hilkka Soininen; Christine West; Jeffery Robbins; Liviu Niculescu
Journal:  Dement Geriatr Cogn Disord       Date:  2006-10-26       Impact factor: 2.959

4.  IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

Authors:  Paramita Chakrabarty; Andrew Li; Carolina Ceballos-Diaz; James A Eddy; Cory C Funk; Brenda Moore; Nadia DiNunno; Awilda M Rosario; Pedro E Cruz; Christophe Verbeeck; Amanda Sacino; Sarah Nix; Christopher Janus; Nathan D Price; Pritam Das; Todd E Golde
Journal:  Neuron       Date:  2015-01-22       Impact factor: 17.173

5.  Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.

Authors:  Peter Parbo; Rola Ismail; Michael Sommerauer; Morten G Stokholm; Allan K Hansen; Kim V Hansen; Ali Amidi; Jeppe L Schaldemose; Hanne Gottrup; Hans Brændgaard; Simon F Eskildsen; Per Borghammer; Rainer Hinz; Joel Aanerud; David J Brooks
Journal:  Neurobiol Dis       Date:  2018-06-11       Impact factor: 5.996

Review 6.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 7.  Environmental and dietary risk factors in Alzheimer's disease.

Authors:  Remi Dosunmu; Jinfang Wu; Md Riyaz Basha; Nasser H Zawia
Journal:  Expert Rev Neurother       Date:  2007-07       Impact factor: 4.618

8.  Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.

Authors:  Joel S Eppig; Emily C Edmonds; Laura Campbell; Mark Sanderson-Cimino; Lisa Delano-Wood; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2017-06-05       Impact factor: 2.892

Review 9.  Relationship between tau pathology and neuroinflammation in Alzheimer's disease.

Authors:  Maria Jose Metcalfe; Maria E Figueiredo-Pereira
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

10.  The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.

Authors:  Rola Ismail; Peter Parbo; Lasse Stensvig Madsen; Allan K Hansen; Kim V Hansen; Jeppe L Schaldemose; Pernille L Kjeldsen; Morten G Stokholm; Hanne Gottrup; Simon F Eskildsen; David J Brooks
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322

View more
  1 in total

1.  The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum.

Authors:  Rachel A Bernier; Sarah J Banks; Matthew S Panizzon; Murray J Andrews; Emily G Jacobs; Douglas R Galasko; Alyx L Shepherd; Katerina Akassoglou; Erin E Sundermann
Journal:  Alzheimers Dement (Amst)       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.